精神分裂症与情感障碍的脑脊液炎症与感染标志物:系统综述与荟萃分析
该系统综述与荟萃分析检索了截至2017年3月23日的脑脊液炎症标志物研究,纳入112项研究,其中32项病例-健康对照研究进入荟萃分析。结果显示精神分裂症和情感障碍患者存在血脑屏障受损和炎症迹象,如脑脊液/血清白蛋白比值、总蛋白、IgG比值及IL-6、IL-8升高等,但证据质量受限。
要点
- 精神分裂症和情感障碍患者脑脊液/血清白蛋白比值和总蛋白升高,提示血脑屏障受损。
- 精神分裂症患者脑脊液IL-6和IL-8水平升高,情感障碍中未显著升高。
- 多数炎症标志物与健康对照无显著差异,证据受偏倚和混杂因素限制。
核心结论
- 精神分裂症和情感障碍可能存在脑脊液异常,包括血脑屏障受损和炎症迹象。
- 现有证据不足以得出确定性结论,因所有研究均存在至少一定程度偏倚且缺乏混杂因素控制。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、CENTRAL、EMBASE、Psychinfo和LILACS至2017年3月23日。
- 纳入112项脑脊液研究(1942-2016年发表),其中32项病例-健康对照研究进入荟萃分析。
主要发现
- 精神分裂症脑脊液/血清白蛋白比值升高(1项研究[54例];SMD=0.71;95%CI 0.33-1.09)。
- 情感障碍脑脊液/血清白蛋白比值升高(4项研究[298例];SMD=0.41;95%CI 0.23-0.60,I2=0%)。
- 精神分裂症总脑脊液蛋白升高(3项研究[97例];SMD=0.41;95%CI 0.15-0.67,I2=0%)。
- 情感障碍总脑脊液蛋白升高(2项研究[53例];SMD=0.80;95%CI 0.39-1.21,I2=0%)。
- 精神分裂症IL-6升高(7项研究[230例];SMD=0.55;95%CI 0.35-0.76;I2=1%)和IL-8升高(3项研究[95例];SMD=0.46;95%CI 0.17-0.75,I2=0%),情感障碍中未显著升高。
关键数值与推荐
- 精神分裂症IgG比值升高(1项研究[54例];SMD=0.68;95%CI 0.30-1.06),IgG白蛋白比值降低(1项研究[32例];SMD=-0.62;95%CI -1.13至-0.12)。
- 无健康对照的研究中脑脊液异常更常见,两项研究发现基于脑脊液的重新诊断率为3.2-6%。
临床怎么用
- 对于精神分裂症和情感障碍患者,脑脊液炎症标志物可能提示血脑屏障受损和炎症过程,但不应作为常规诊断依据。
- 在考虑抗炎治疗前,需进一步研究确认脑脊液炎症亚组的潜在获益。
局限性
- 所有研究均存在至少一定程度偏倚,且 vastly 缺乏混杂因素(如性别、年龄、病程、治疗等)的纳入。
- 仅少数研究用健康对照调查相同参数,缺乏高质量纵向脑脊液研究,包括精神药物、生活方式因素及抗炎治疗获益的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Infections and inflammatory processes have been associated with the development of schizophrenia and affective disorders; however, no study has yet systematically reviewed all available studies on cerebrospinal fluid (CSF) immune alterations. We aimed to systematically review the CSF immunological findings in schizophrenia spectrum and affective disorders. We identified all studies investigating CSF inflammatory markers in persons with schizophrenia or affective disorders published prior to March 23, 2017 searching PubMed, CENTRAL, EMBASE, Psychinfo, and LILACS. Literature search, data extraction and bias assessment were performed by two independent reviewers. Meta-analyses with standardized mean difference (SMD) including 95% confidence intervals (CI) were performed on case-healthy control studies. We identified 112 CSF studies published between 1942-2016, and 32 case-healthy control studies could be included in meta-analyses. Studies varied regarding gender distribution, age, disease duration, treatment, investigated biomarkers, and whether recruitment happened consecutively or based on clinical indication. The CSF/serum albumin ratio was increased in schizophrenia (1 study [54 patients]; SMD = 0.71; 95% CI 0.33-1.09) and affective disorders (4 studies [298 patients]; SMD = 0.41; 95% CI 0.23-0.60, I2 = 0%), compared to healthy controls. Total CSF protein was elevated in both schizophrenia (3 studies [97 patients]; SMD = 0.41; 95% CI 0.15-0.67, I2 = 0%) and affective disorders (2 studies [53 patients]; SMD = 0.80; 95% CI 0.39-1.21, I2 = 0%). The IgG ratio was increased in schizophrenia (1 study [54 patients]; SMD = 0.68; 95% CI 0.30-1.06), whereas the IgG Albumin ratio was decreased (1 study [32 patients]; SMD = -0.62; 95% CI -1.13 to -0.12). Interleukin-6 (IL-6) levels (7 studies [230 patients]; SMD = 0.55; 95% CI 0.35-0.76; I2 = 1%) and IL-8 levels (3 studies [95 patients]; SMD = 0.46; 95% CI 0.17-0.75, I2 = 0%) were increased in schizophrenia but not significantly increased in affective disorders. Most of the remaining inflammatory markers were not significantly different compared to healthy controls in the meta-analyses. However, in the studies which did not include healthy controls, CSF abnormalities were more common, and two studies found CSF dependent re-diagnosis in 3.2-6%. Current findings suggest that schizophrenia and affective disorders may have CSF abnormalities including signs of blood-brain barrier impairment and inflammation. However, the available evidence does not allow any firm conclusion since all studies showed at least some degree of bias and vastly lacked inclusion of confounding factors. Moreover, only few studies investigated the same parameters with healthy controls and high-quality longitudinal CSF studies are lacking, including impact of psychotropic medications, lifestyle factors and potential benefits of anti-inflammatory treatment in subgroups with CSF inflammation.
引用
- Orlovska-Waast S, Köhler-Forsberg O, Brix SW, et al. Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis. Mol Psychiatry. 2018. PMID: 30116031. doi:10.1038/s41380-018-0220-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。